China Biologic Products (CBPO) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2017
February 28, 2018 5:00 PM ESTBEIJING, Feb. 28, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2017.
Fourth Quarter 2017 Financial Highlights
Total sales in the fourth quarter of 2017 increased by 12.2% in RMB terms and 16.1% in USD terms to $90.1 million from $77.6 million in the same quarter of 2016. Gross profit increased by 26.7% to $59.3 million from $46.8 million in the same quarter of 2016. Gross margin increased to 65.8% from 60.3% in the... More